Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Liquidia's enterprise value is €6,021.9 Mil.
Liquidia's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €153.8 Mil. Therefore, Liquidia's EV-to-EBITDA for today is 39.15.
The historical rank and industry rank for Liquidia's EV-to-EBITDA or its related term are showing as below:
FRA:LT4'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -86.93 Med: -6.88 Max: 146.22
Current: 39.09
During the past 10 years, the highest EV-to-EBITDA of Liquidia was 146.22. The lowest was -86.93. And the median was -6.88.
FRA:LT4's EV-to-EBITDA is ranked worse than 83.65% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs FRA:LT4: 39.09
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Liquidia's share price for today is €68.82.
Liquidia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.186.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Liquidia's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LT4 vs LNTH, ALKS, HIMS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liquidia's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Liquidia's EV-to-EBITDA falls into.
Liquidia's current Enterprise Value is €6,021.9 Mil.
Liquidia's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €153.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia (FRA:LT4) has a EV-to-EBITDA of 39.15 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Liquidia. According to the industry distribution chart, Liquidia ranks #614 out of 734 companies in the Drug Manufacturers industry, placing it in the top 83.7%.
Is Liquidia's EV-to-EBITDA too high?
Liquidia's current EV-to-EBITDA is 39.15. The Drug Manufacturers industry median EV-to-EBITDA is 13.36. Liquidia's value of 39.15 is 193.1% above this industry median. Based on the distribution chart, Liquidia ranks #614 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liquidia has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's EV-to-EBITDA compare to LNTH and ALKS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #614 out of 734 companies for EV-to-EBITDA. This places Liquidia in the lower half of its industry. The industry median EV-to-EBITDA is 13.36. Liquidia's value of 39.15 is 193.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current EV-to-EBITDA of 39.15 is 193.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Liquidia. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current EV-to-EBITDA is 39.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (FRA:LT4) is currently considered Possible Value Trap. The stock's GF Value™ is €230.61, compared to a current price of €68.82 — trading 70.2% below its estimated fair value. The current EV-to-EBITDA is 39.15 and 193.1% above the Drug Manufacturers industry median of 13.36. Liquidia's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Liquidia (FRA:LT4), the current EV-to-EBITDA is 39.15 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liquidia (FRA:LT4) Overvalued in 2026?
Based on GuruFocus' analysis, Liquidia stock appears to be undervalued.
The current stock price of €68.82 is trading 70.2% below its estimated GF Value™ of €230.61.
GuruFocus considers Liquidia to be Possible Value Trap.
Key valuation signals for FRA:LT4:
EV-to-EBITDA: 39.15
GF Value™: €230.61 vs. price of €68.82 (70.2% below fair value)
Industry Position: 193.1% above the Drug Manufacturers median (#614 of 734)
No single metric tells the full story. See the FRA:LT4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
75GF Score
Get the complete analysis for FRA:LT4
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LT4 has been successfully added to your 
